NCT03620578 - DA-EPOCH-R Induction Followed by Nivolumab Consolidation in Newly Diagnosed MYC, BCL2 and/or BCL6 Rearranged HGBL | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 1, 2018

Primary Completion Date

January 30, 2024

Study Completion Date

October 31, 2026

Conditions

Non Hodgkin LymphomaLymphoma, B-CellHigh-grade B-cell LymphomaMYC TranslocationBCL-2 Translocation

Interventions

DRUG

DA-EPOCH-R followed by Nivolumab

5 induction cycles of DA-EPOCH-R protocol, for patient with Deauville imaging response criteria proven complete metabolic response followed with one year Nivolumab consolidation therapy

Trial Locations (24)

Unknown

BE-Antwerpen-ZNASTUIVENBERG, Antwerp

BE-Leuven-UZLEUVEN, Leuven

NL-Den Bosch-JBZ, 's-Hertogenbosch

NL-Almere-FLEVOZIEKENHUIS, Almere Stad

NL-Amersfoort-MEANDERMC, Amersfoort

NL-Amsterdam-AMC, Amsterdam

NL-Amsterdam-VUMC, Amsterdam

NL-Eindhoven-MAXIMAMC, Eindhoven

NL-Enschede-MST, Enschede

NL-Goes-ADRZ, Goes

NL-Groningen-UMCG, Groningen

NL-Hoofddorp-SPAARNEGASTHUIS, Hoofddorp

NL-Hoorn-DIJKLANDERHOORN, Hoorn

NL-Leeuwarden-MCL, Leeuwarden

NL-Leiden-LUMC, Leiden

NL-Maastricht-MUMC, Maastricht

NL-Nijmegen-RADBOUDUMC, Nijmegen

NL-Rotterdam-ERASMUSMC, Rotterdam

NL-Rotterdam-MAASSTADZIEKENHUIS, Rotterdam

NL-Sittard-Geleen-ZUYDERLAND, Sittard

NL-Den Haag-HAGA, The Hague

NL-Tilburg-ETZ, Tilburg

NL-Utrecht-UMCUTRECHT, Utrecht

NL-Zwolle-ISALA, Zwolle

All Listed Sponsors

lead

Stichting Hemato-Oncologie voor Volwassenen Nederland

OTHER